Labcorp Acquires Myriad Genetics Prenatal Testing Unit

The $210 million deal strengthens Labcorp's reproductive health portfolio and specialty testing growth strategy.

Updated on Oct. 21, 2026 in Healthcare

Labcorp Acquires Myriad Genetics Prenatal Testing Unit

Live Poll

Do you trust that consolidation among large medical testing companies improves the quality of patient care?

Labcorp has agreed to acquire Myriad Genetics's prenatal health testing business for $210 million in cash. This deal, scheduled to close in early 2027, adds a reproductive genetics platform to Labcorp's existing women's health portfolio.

Why it matters

The acquisition reflects Labcorp's ongoing strategy to expand its specialty testing operations through targeted clinical assets. By integrating this platform, the company aims to scale its reproductive genetics capabilities, with expected revenue of $160 million in the first year of operation.

Labcorp is purchasing the business for $210 million in cash, adding to a total of $2.3 billion invested in 12 acquisitions since 2023. The new unit is expected to contribute $160 million in revenue during its first year.

The players

Labcorp

A global diagnostics and drug development company headquartered in Burlington, North Carolina, focused on expanding its specialty testing market share.

Myriad Genetics

A precision medicine company that is divesting its prenatal health testing assets to focus on other core genetic testing operations.

The details

The transaction includes the transfer of the unit's prenatal health inventory, which will be folded into Labcorp's existing women's health offerings. Labcorp expects the business to reach its average diagnostics segment margins by the end of the second year post-closing. This follows a broader investment cycle that saw the company spend $225 million on BioReference Health's oncology operations in 2025.

2023: Labcorp initiated its current cycle of 12 acquisitions.
2025: Labcorp acquired BioReference Health's oncology operations.
September 2026: The company hosted an Analyst/Investors Day call.
October 20, 2026: The acquisition of Myriad Genetics's prenatal unit was announced.
Early 2027: The transaction is scheduled to close.

Market Landscape

The acquisition aligns with a multi-year consolidation trend among national diagnostic laboratories seeking to integrate specialized testing platforms. This deal follows the pattern of Labcorp's previous $722 million acquisition of BioReference Health's laboratory operations.

Specialty testing providers should monitor Labcorp's expanding market footprint as the firm scales its reproductive genetics segment. Operators in the prenatal testing space should anticipate increased competitive pressure on diagnostics pricing and service integration once the deal closes.

The takeaway

Labcorp is aggressively diversifying its diagnostic revenue streams by absorbing niche specialty players. Operators should monitor the target margin performance of this new business in 2028 to gauge the long-term success of the company's $2.3 billion acquisition cycle.